You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
京新藥業(002020.SZ)業績快報:2019年淨利升40.27%至5.19億元
格隆匯 02-26 17:49

格隆匯2月26日丨京新藥業(002020.SZ)披露2019年度業績快報,報告期內,公司實現營業總收入36.46億元,同比增長23.84%,主要是藥品和醫療器械業務快速增長所致。

2019年度,公司繼續圍繞“做強藥品主業,發展醫療器械”的經營方針,通過體制和機制改革、研發創新、人才隊伍建設,積極提升藥品營銷力、重點產品競爭力,主營業務持續快速增長,其中成品藥營收21.92億元、同比增長30.59%;原料藥營收9.38億元、同比增長10.61%;醫療器械營收4.74億元、同比增長23.57%。

報告期內,公司實現營業利潤5.81億元,同比增長39.64%;利潤總額5.83億元,同比增長40.40%;淨利潤5.19億元,同比增長40.27%。主要是主營業務收入增長所致。公司業績持續快速發展離不開研發的深耕細作,2019年公司研發投入3億元,同比增長23.81%,主要是圍繞公司戰略進行產品管線的佈局。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account